Alok Srivastava

Alok Srivastava


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
VMVikram Mathews
Vikram Mathews
SNSukesh C Nair
Sukesh C Nair
SDSachin David
Sachin David
AVAuro Viswabandya
Auro Viswabandya
ASAlok Srivastava
Alok Srivastava
Data are limited on inhibitors in people with hemophilia (PWH) in developing countries. There is a perception that the overall prevalence of inhibitors, ranging from 7 to 19% in different reports, may be lower in these countries as compared with that reported from developed countries. This is possible given the fact that most patients are treated after 2 years of age with plasma-derived clotting factor concentrates. Whether genetic or other environmental factors also contribute to this needs further evaluation. There is a need to develop laboratory infrastructure and establish quality control programs for laboratory tests for inhibitors in developing countries. Management options vary widely given the socioeconomic diversity among these countries. Significant individualization of approach to management is therefore required depending on the available resources, particularly with regard to the use of bypassing agents. The limited data on immune tolerance induction with some low-dose regimens deserve further evaluation. Even in resource-constrained environments, education and a policy of systematic screening of patients associated with judicious use of bypassing agents can significantly improve the care of PWH who develop inhibitors.

30 August 2024 in Transplantation Proceedings
Verified
Journal Article
Closed access
NRNandan Rai
Nandan Rai
ASAlok Srivastava
Alok Srivastava
SSSanjeet Kumar Singh
Sanjeet Kumar Singh
IDIshwar Ram Dhayal
Ishwar Ram Dhayal
AKAnkit Kumar
Ankit Kumar
ASAmit Sachdeva
Amit Sachdeva

23 April 2026 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
AGAnkit Gupta
Ankit Gupta
SCSubrat Chandra
Subrat Chandra
TVTripti Verma
Tripti Verma
AGAnurag Gupta
Anurag Gupta
PSPradyumn Singh
Pradyumn Singh
ASAlok Srivastava
Alok Srivastava

18 December 2024 in BJUI Compass
Verified
Journal Article
Open access
VSVikram Singh
Vikram Singh
IDIshwar Ram Dhayal
Ishwar Ram Dhayal
SSSanjeet Kumar Singh
Sanjeet Kumar Singh
ASAlok Srivastava
Alok Srivastava
NRNandan Rai
Nandan Rai
Objective: To determine whether the position of the bolster affects the access tract (supracostal/infracostal) for a superior calyceal puncture during prone PCNL and its effect on pleural complications.Materials and Methods: It was a randomized clinical trial. Patients in whom superior calyceal puncture was done were divided into two groups by systematic sampling method, group 1 (horizontal bolster) and group 2 (vertical bolster), 50 patients in each group. Standard PCNL was perfomed in all patients. Chest x‐ray was done on POD 0 (postoperative day) and POD 1 for assessment of pleural complication. NCCT KUB was done on POD 1 for assessment of stone clearance.Results: In group 1, 36 patients (72%) underwent supracostal puncture and 14 patients (28%) underwent infracostal puncture while in group 2, 38 patients (76%) underwent supracostal puncture and 14 patients (28%) underwent infracostal puncture (p‐value‐ 0.820). Two patients (4%) in group 1 & three patients in group 2 had pleural complications in the form of hydrothorax (p‐value‐ 0.666). Four patients in group 1 and five patients in group 2 underwent ancillary procedure for clearance of residual stones.Conclusion: In our study, the orientation of the bolster either horizontal or vertical does not affect the site of puncture during prone PCNL which probably resulted in no difference in pleural complications in two groups.